European Surgical Research
Original Paper
The Expression of rac1 Pseudogene in Human Tissues and in Human Brain TumorsHwang S.L.a · Chang J.H.b · Cheng C.Y.a · Howng S.L.a · Sy W.D.b · Lieu A.S.a · Lin C.L.a · Lee K.S.a · Hong Y.R.baDivision of Neurosurgery, and bBiochemistry Institute, Kaohsiung Medical University, Kaohsiung, Taiwan
Keywords: |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: June 08, 2004
Accepted: October 12, 2004
Published online: May 19, 2005
Issue release date: March – April
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Abstract
Background: Recent studies have demonstrated that Rac is a regulator of cell morphology and growth. Rac1 gene appears to have involvement in tumorigenesis and metastatic potential. In our previous study of rac1 gene in 45 human brain tumors, rac1 pseudogene was found. The rac1 pseudogene is an intronless pseudogene and has a similarity of 86% with rac1 nucleotide sequence. The rac1 pseudogene contains 579 nucleotides and only 46 amino acids can be translated. Little is known about the expression of rac1 pseudogene in human tissues or tumors. Materials and Methods: The expression of rac1 gene and rac1 pseudogene in different human tissues and brain tumors was investigated by the use of reverse transcriptase-polymerase chain reaction and Northern blotting. Results: The rac1 gene is apparently expressed in these 8 human tissues. The rac1 pseudogene is also apparently expressed in human tissues except for brain tissue. The overexpression of rac1 gene in brain tumors was 8% (2/25) and the overexpression of rac1 pseudogene was 76.9% (20/26). Only two astrocytomas had overexpression of rac1 gene, compared with normal brain tissues. The overexpression of rac1 pseudogene was 6 of 9 in meningiomas, 7 of 9 in astrocytomas, and 7 of 8 in pituitary adenomas. Conclusions: High frequency of overexpression of rac1 pseudogene was detected in the human brain tumors when compared with that expressed in the normal brain tissues. Our study suggested that the rac1 pseudogene may play an important role of the tumorigenesis of brain.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R: rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 1989;264:16378–16382.
- Shirsat NV, Pignolo RJ, Kreider BL, Rovera G: A member of the ras gene superfamily is expressed specifically in T, B and myeloid hemopoietic cells. Oncogene 1990;5:769–772.
- Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, Field J: Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997;17:4454–4464.
- Tang Y, Yu J, Field J: Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol Cell Biol1999;19:1881–1891.
- Olson MF, Ashworth A, Hall A: An essential role for Rho, Rac and Cdc42 GTPases in cell cycle progression through G1. Science1995;269:1270–1272.
-
Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ: Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation.Mol Cell Biol1995;15:6443–6453.
- Zhao ZS, Manser E, Chen XQ, Chong C, Leung T, Lim L: A conserved negative regulatory region in alphaPAK: Inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol Cell Biol1998;18:2153–2163.
- Sells MA, Boyd JT, Chernoff J: p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol1999;145:837–849.
- Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG: A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 1995;375:338–340.
- Schmitz A, Govek E, Bottner B, Van Aelst L: Rho GTPases: Signaling, migration and invasion. Exp Cell Res2000;261:1–12.
- Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, Collard JG: Rho family proteins in cell adhesion and cell migration. Eur J Cancer 2000;36:1269–1274.
- Senger DL, Tudan C, Guiot MC, Mazzoni IE, Molenkamp G, LeBlanc R, Antel J, Olivier A, Snipes GJ, Kaplan DR: Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res2002;62:2131–2140.
- Hwang SL, Hong YR, Sy WD, Lieu AS, Lin CL, Lee KS, Howng SL: Rac1 gene mutations in human brain tumors. Eur J Surg Oncol 2004;30:68–72.
- Mighell AJ, Smith NR, Robinson PA, Markham AF: Vertebral pseudogenes. FEBS Lett 2000;468:109–114.
- Vanin EF: Processed pseudogenes: Characteristics and evolution. Annu Rev Genet 1985;19:253–272.
- McCarrey JR, Kumari M, Aivaliotis MJ, Wang Z, Zhang P, Marshall F, Vandeberg JL: Analysis of the cDNA and encoded protein of the human testis-specific PGK-2 gene. Dev Genet 1996;19:321–332.
- Fujii GH, Morimoto AM, Berson AE, Bolen JB: Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene1999;18:1765–1769.
- Olsen MA, Schechter LE: Cloning, mRNA localization and evolutionary conservation of a human 5-HT7 receptor pseudogene. Gene 1999;227:63–69.
- Haataja L, Groffen J, Heisterkamp N: Characterization of rac3, a novel member of the Rho family. J Biol Chem 1997;272:20384–20388.
- Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in human breast tumors: Expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87:635–644.
- Lozano E, Betson M, Braga VMM: Tumor progression: Small GTPases and loss of cell-cell adhesion. Bioessays 2003;25:452–463.
Article / Publication Details
Received: June 08, 2004
Accepted: October 12, 2004
Published online: May 19, 2005
Issue release date: March – April
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
